Atara Biotherapeutics Valuation

ATRA Stock  USD 0.69  0.01  1.43%   
Atara Biotherapeutics is overvalued. Atara Biotherapeutics shows a prevailing Real Value of $0.64 per share. The current price of the firm is $0.69. Our model approximates the value of Atara Biotherapeutics from analyzing the firm fundamentals such as return on equity of -4.26, and Operating Margin of (32.56) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor taking in undervalued instruments and trading overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Price Book
1.9674
Enterprise Value
30.7 M
Enterprise Value Ebitda
(0.09)
Price Sales
15.5912
Enterprise Value Revenue
6.7683
Overvalued
Today
0.69
Please note that Atara Biotherapeutics' price fluctuation is out of control at this time. Calculation of the real value of Atara Biotherapeutics is based on 3 months time horizon. Increasing Atara Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Atara Biotherapeutics is useful when determining the fair value of the Atara stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Atara Biotherapeutics. Since Atara Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Atara Stock. However, Atara Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.69 Real  0.64 Target  14.72 Hype  0.69 Naive  0.73
The real value of Atara Stock, also known as its intrinsic value, is the underlying worth of Atara Biotherapeutics Company, which is reflected in its stock price. It is based on Atara Biotherapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Atara Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Atara Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
0.64
Real Value
10.82
Upside
Estimating the potential upside or downside of Atara Biotherapeutics helps investors to forecast how Atara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Atara Biotherapeutics more accurately as focusing exclusively on Atara Biotherapeutics' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-0.67-0.48-0.59
Details
Hype
Prediction
LowEstimatedHigh
0.030.6910.87
Details
Naive
Forecast
LowNext ValueHigh
0.010.7310.91
Details
7 Analysts
Consensus
LowTarget PriceHigh
13.4014.7216.34
Details

Atara Biotherapeutics Investments

173.4 Million

Atara Biotherapeutics Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Atara Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Atara Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atara Biotherapeutics competition to find correlations between indicators driving Atara Biotherapeutics's intrinsic value. More Info.
Atara Biotherapeutics is rated second in price to book category among related companies. It is rated second in beta category among related companies totaling about  0.49  of Beta per Price To Book. The ratio of Price To Book to Beta for Atara Biotherapeutics is roughly  2.05 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Atara Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Atara Biotherapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Atara Biotherapeutics' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Atara Biotherapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Atara Biotherapeutics and how it compares across the competition.

About Atara Biotherapeutics Valuation

The stock valuation mechanism determines the current worth of Atara Biotherapeutics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Atara Biotherapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Atara Biotherapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Atara Biotherapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Atara Biotherapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Atara Biotherapeutics. We calculate exposure to Atara Biotherapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Atara Biotherapeutics's related companies.
Last ReportedProjected for 2024
Gross Profit-313 K-297.4 K
Pretax Profit Margin(32.21)(33.82)
Operating Profit Margin(32.19)(33.80)
Net Loss(32.21)(33.82)
Gross Profit Margin(0.04)(0.03)

8 Steps to conduct Atara Biotherapeutics' Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Atara Biotherapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Atara Biotherapeutics' valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Atara Biotherapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Atara Biotherapeutics' revenue streams: Identify Atara Biotherapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Atara Biotherapeutics' industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Atara Biotherapeutics' growth potential: Evaluate Atara Biotherapeutics' management, business model, and growth potential.
  • Determine Atara Biotherapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Atara Biotherapeutics' estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Atara Biotherapeutics Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Atara Biotherapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding105.9 M

Atara Biotherapeutics Current Valuation Indicators

Valuation refers to the process of determining the present value of Atara Biotherapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Atara we look at many different elements of the entity such as Atara's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Atara Biotherapeutics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Atara Biotherapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Atara Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Atara Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Atara Biotherapeutics' worth.
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Atara Stock analysis

When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bonds Directory
Find actively traded corporate debentures issued by US companies
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is Atara Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Revenue Per Share
0.043
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.64)
Return On Equity
(4.26)
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.